| Equation | (# participants) x (% individuals screened/treated solely because of the program) x (# QALY increase) x ($ QALY) |
| Explanation | This metric estimates the impact of screening for sexually transmitted diseases (STI) on lifetime health, estimated in terms of quality-adjusted life years (QALY). Number of participants: Reported by program. Percentage of participants receiving test/treatment due to program: The counterfactual is based on the percent of low-income female and male individuals who are tested for sexually transmitted illnesses in the U.S.A. An estimated 80% of women are tested and 7% of men (Cuffe, et al.,2016).
QALY increase: [0.4]. Based on findings from Beck, et al. (2016). $ value per QALY: [$50,000] Benefits are then discounted to present value based on the average age of participation to life expectancy. |
| References | Beck, E., Armbruster, B., Birkett, M., & Mustanski, B. (2016). PRM51 – The Benefits of A Holistic View: Considering Multiple Health Outcomes for HIV and STI Testing. Value in Health, 19(7), A366. Cuffe, K. M., Newton-Levinson, A., Gift, T. L., McFarlane, M., & Leichliter, J. S. (2016). Sexually Transmitted Infection Testing Among Adolescents and Young Adults in the United States. Journal of Adolescent Health, 58(5), 512–519. |
HEA019 STI screening and treatment leading to increased quality-adjusted life years (QALY)
